Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Erratum

Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]

Clinical and Molecular Hepatology 2025;31(3):1103-1104.
Published online: July 1, 2025

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

2Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

3Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

4Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

5Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Corresponding author : Ju Dong Yang Cedars-Sinai Medical Center, 8900 Beverly Blvd, Los Angeles, CA 90048, USA Tel: +1-310-423-1971, Fax: +1-310-423-2356, E-mail: judong.yang@cshs.org

Copyright © 2025 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 5,596 Views
  • 12 Download
prev next
This corrects the article "Systemic therapy in advanced hepatocellular carcinoma" on page 516.
There was an error in the table: “Phase III Trials of First-line Systemic Therapy for advanced HCC”
The PR for HIMALAYA (2022) trial was entered as 65.8% for Durva/Tre, 57.8% for Durva, and 63.2% for Sorafenib. However, those values actually refer to the proportion of patients remaining in response at 12 months.
The corrected PR values should be 17.0% for Durva/Tre, 15.4% for Durva, and 5.1% for Sorafenib.
After correction
cmh-2023-0051ef1.jpg

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]
Clin Mol Hepatol. 2025;31(3):1103-1104.   Published online July 1, 2025
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]
Clin Mol Hepatol. 2025;31(3):1103-1104.   Published online July 1, 2025
Close

Figure

  • 0
Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]
Image
Graphical abstract
Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]